Melanoma clinical trials
Showing 201–250 of 257 active trials. Describe your situation to see which ones you may be eligible for.
- Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
- High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
- Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
- Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
- The Florida ASCENT Study
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
- Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
- Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
- Video Education With Result Dependent dIsclosure
- Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
- Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
- A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
- Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
- Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
- Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
- Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
- Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma
- Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.
- Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
- PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
- Evaluating a Decision Aid for Sentinel Lymph Node Biopsy in Intermediate-Risk Melanoma
- Investigating Participation Patterns Among Stage IV Melanoma Patients
- Clinical Genetics Branch Eligibility Screening Survey
- Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
- Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
- Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
- Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study
- A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
- Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery
- Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
- Natural History Study of Early Life Exposures in Agriculture (ELEA)
- Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
- Harvesting Cells for Experimental Cancer Treatments
- Clinical Trial to Treat Stage IV Cancer Patients
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
- A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
- Axitinib + Ipilimumab in Advanced Melanoma
- Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
- A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
- A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.